Literature DB >> 25207183

Clinicopathological Characteristics of Triple-negative Breast Cancers in the Northeast Region of Turkey.

Bülent Yıldız1, Evren Fidan2, Feyyaz Ozdemir3, Orhan Sezen4, Halil Kavgacı3, Fazıl Aydın3.   

Abstract

BACKGROUND: Triple-negative (TN) breast cancer is a subtype of breast cancer characterised by a loss of estrogen receptor (ER), progesterone receptor (PR) expression, and the absence of human epidermal growth factor (HER2) overexpression. AIMS: To identify the relationships between clinicopathological characteristics of TN breast cancers in the northeast region of Turkey and disease free survival (DFS) and overall survival (OS). STUDY
DESIGN: Retrospective clinical study.
METHODS: Seven hundred and eighty non-metastatic breast cancer patients were enrolled in this study. The relationships between TN breast cancer and other breast cancers with respect to clinicopathological characteristics, as well as DFS and OS, were studied.
RESULTS: The triple-negative phenotype was detected in 204 patients (27.1%). Patients with triple-negative breast cancer had more grade 2-3 tumours compared to those with other types of breast cancer (92.5% versus 84.3%, p=0.004). Invasive ductal carcinoma histology, on the other hand, was less prevalent in patients with TN breast cancer (77% versus 84.5%, p=0.016). No significant differences were identified between the groups in other clinicopathological variables. Relapse and mortality rates were higher in the TN group during the follow-up of both groups [57 (27.9%) versus 89 (16.2%), p<0.001 for relapse; 27 (13.2%) versus 37 (6.8%), p=0.005 for mortality]. The univariate analysis demonstrated shorter DFS and OS for patients with TN breast cancer compared to those with other types of breast cancer. In the multivariate analysis, patients with TN breast cancer were 2.21 times more likely to develop relapse, while the likelihood of death increased 3.21-fold (p<0.001 and p<0.001).
CONCLUSION: Triple-negative breast cancers demonstrate a more aggressive clinical course compared to other breast cancers. More effective strategies should be developed for the treatment of this subgroup of breast cancer.

Entities:  

Keywords:  Breast neoplasms; disease free survival; overall survival

Year:  2014        PMID: 25207183      PMCID: PMC4115936          DOI: 10.5152/balkanmedj.2014.13143

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  23 in total

1.  High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.

Authors:  Dalia M Abd El-Rehim; Graham Ball; Sarah E Pinder; Emad Rakha; Claire Paish; John F R Robertson; Douglas Macmillan; Roger W Blamey; Ian O Ellis
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

2.  Prognostic markers in triple-negative breast cancer.

Authors:  Emad A Rakha; Maysa E El-Sayed; Andrew R Green; Andrew H S Lee; John F Robertson; Ian O Ellis
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  [Clinical characteristics comparison between triple-negative and non-triple-negative breast cancer].

Authors:  Hui-ming Zhang; Li-xue Xuan; Ji-dong Gao; Bao-ning Zhang; Ping Zhao
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2009-04-01

5.  The prognostic importance of triple negative breast carcinoma.

Authors:  Hakan Mersin; Emin Yildirim; Ugur Berberoglu; Kaptan Gülben
Journal:  Breast       Date:  2008-05-01       Impact factor: 4.380

6.  Is triple negative a prognostic factor in breast cancer?

Authors:  Reiki Nishimura; Nobuyuki Arima
Journal:  Breast Cancer       Date:  2008-03-29       Impact factor: 4.239

7.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Authors:  Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

8.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

9.  The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

Authors:  Jiyoung Rhee; Sae-Won Han; Do-Youn Oh; Jee Hyun Kim; Seock-Ah Im; Wonshik Han; In Ae Park; Dong-Young Noh; Yung-Jue Bang; Tae-You Kim
Journal:  BMC Cancer       Date:  2008-10-23       Impact factor: 4.430

10.  E-cadherin expression in primary carcinomas of the breast and its distant metastases.

Authors:  Paul J Kowalski; Mark A Rubin; Celina G Kleer
Journal:  Breast Cancer Res       Date:  2003-09-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.